Larisa Layug
About Larisa Layug
Larisa Layug is a Director of Business and Technology Transformation at EmblemHealth, where she has worked since 2015. She has extensive experience in the healthcare sector, having held various roles at Deloitte and other organizations.
Work at EmblemHealth
Larisa Layug has been with EmblemHealth since 2015, where she currently serves as Account Director for the ePMO, Government Programs. In 2016, she was promoted to Director of Business and Technology Transformation. Her tenure at EmblemHealth spans over nine years, during which she has described her experience as both challenging and enjoyable. She collaborates with a high-performing team that focuses on problem-solving and achieving outcomes. The team is characterized by its diverse backgrounds and expertise in various areas, including technology, business operations, systems testing, and program delivery.
Previous Experience at Deloitte
Larisa Layug worked at Deloitte for a total of seven years from 2001 to 2008, initially as a Manager. She later took on the role of Senior Manager in Health Sciences, Market Intelligence, Research, Brand & Innovation from 2008 to 2011. Additionally, she served as a Team Leader in Life Sciences and Healthcare Market Insights within the Deloitte Eminence Group from 2012 to 2015. This extensive experience at Deloitte allowed her to develop expertise in market insights and health sciences.
Education and Expertise
Larisa Layug holds an AB degree from Dartmouth College, where she also served as a Lombard Fellow from 1996 to 1997. Her educational background, combined with her professional experience, has equipped her with a strong foundation in business and technology transformation. She also attended Newton Country Day School, further contributing to her academic and professional development.
Background in Health Sciences and Market Insights
Before her tenure at Deloitte, Larisa Layug worked as an Analyst II at the Lewin Group from 1998 to 2000 and as a Senior Analyst at Scient for a brief period in 2000. These roles provided her with early exposure to health sciences and market analysis, which she later expanded upon during her time at Deloitte and EmblemHealth.